Mercury Biopharmaceutical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	5.75	1.03	2.68	-	-	-
Revenue Growth (YoY)	114.55%	-61.46%	-	-	-	-
Cost of Revenue	1.18	0.44	1.51	-	-	-
Gross Profit	4.57	0.59	1.17	-	-	-
Selling, General & Admin	26.79	24.91	16.66	2.48	0.21	0.2
Research & Development	24.58	21.37	15.41	2.82	-	-
Operating Expenses	51.37	46.28	32.07	5.3	0.21	0.2
Operating Income	-46.8	-45.69	-30.9	-5.3	-0.21	-0.2
Interest Expense	-0.74	-0.71	-0.4	-0.01	-	-
Interest & Investment Income	4.49	3.07	0.33	0	-	-
Currency Exchange Gain (Loss)	0.15	0	-0.06	-	-	-
Other Non Operating Income (Expenses)	-0.48	-0.48	-0.22	-	-	-
Pretax Income	-43.39	-43.82	-31.25	-5.31	-0.21	-0.2
Net Income	-43.41	-43.82	-31.25	-5.31	-0.21	-0.2
Net Income to Common	-43.41	-43.82	-31.25	-5.31	-0.21	-0.2
Shares Outstanding (Basic)	416	410	376	277	104	-
Shares Outstanding (Diluted)	416	410	376	277	104	-
Shares Change (YoY)	3.20%	9.00%	36.09%	165.94%	-	-
EPS (Basic)	-0.10	-0.11	-0.08	-0.02	-0.00	-
EPS (Diluted)	-0.10	-0.11	-0.08	-0.02	-0.00	-
Free Cash Flow	-40.56	-55.07	-94.35	-11.77	-0.22	-0.2
Free Cash Flow Per Share	-0.10	-0.13	-0.25	-0.04	-0.00	-
Gross Margin	79.44%	57.31%	43.73%	-	-	-
Operating Margin	-813.96%	-4423.04%	-1152.91%	-	-	-
Profit Margin	-755.01%	-4241.63%	-1166.05%	-	-	-
Free Cash Flow Margin	-705.41%	-5331.17%	-3520.60%	-	-	-
EBITDA	-42.29	-42.69	-29.15	-4.73	-	-
D&A For EBITDA	4.51	3	1.75	0.57	-	-
EBIT	-46.8	-45.69	-30.9	-5.3	-0.21	-0.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.